NAD Supplement Manufacturer: OEM and Private Label for NR and NMN

We are a contract manufacturer in Guangzhou producing NAD precursor capsules, powder stick packs and tablets. This page separates the chemistry from the regulatory status, because NMN and NR are not interchangeable in law. We verify the destination market before locking a formula.

23 years
contract manufacturing experience
500 units
MOQ for most capsule and tablet runs
4–6 weeks
pilot lead time after artwork approval
NAD Supplement Manufacturer: OEM and Private Label for NR and NMN

What you are actually manufacturing

NAD+ itself is not orally bioavailable in a useful way, so the commercial category is built on precursors: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), plus niacin and nicotinamide. Your customer is buying a precursor dose in a capsule, stick pack or tablet, not NAD+ as a molecule. That distinction matters for your label and for your regulatory file. We manufacture the finished dosage form in-house: hard capsules, powder sachets, stick packs and tablets. We do not make claims about anti-ageing or longevity; those are your regulatory and marketing decisions, and they differ by market.

The legal side is where most projects stall. NMN has been excluded from the dietary supplement definition in the US by FDA, and the EU has not authorised it as a novel food. NR has been through the EU novel food process. Status changes, so it must be re-checked per destination market and per year before a formula is locked. A formula that ships to one market may not be sellable in another. We ask for the destination market and the intended regulatory pathway before we quote a capsule or stick pack, because the answer changes the label, the claims and sometimes the ingredient itself.

What we control in the factory

Precursor-specific handling
NR and NMN are moisture- and heat-sensitive. We treat packaging as part of the formula decision, not an afterthought. Aluminium blister, HDPE with desiccant and foil stick packs are specified against your stability protocol, not chosen from a catalogue.
Capsules and stick packs
Hard capsules, often DRcaps-style acid-resistant, and powder stick packs are the common formats for this category. We run both in-house. Tablets are available where the dose and the excipient profile allow compression without excessive heat exposure.
Assay by HPLC
Potency is measured by HPLC. Buyers should ask for the actual potency method and a stability protocol, not just a CoA on the raw material. We provide a CoA per batch and can discuss the method behind the number before you commit to a specification.
Regulatory check first
Before a formula is locked we confirm the status of NMN or NR for the destination market. US dietary supplement exclusion and EU novel food status are re-verified per year. We do not state a regulatory status as permanent, because it is not.
Pilot runs from 500
Most capsule and tablet forms start at 1,000 units. Softgels can start at 1,000 pieces for a pilot. Gummies and stick packs need higher first runs. Sampling takes 7–10 days; a pilot run takes 4–6 weeks after formula and artwork approval.
Export documents
Each batch ships with a CoA. Export documents include certificate of origin, health certificate and MSDS where relevant. We serve the US, UK, EU, Canada, Australia, Middle East and Southeast Asia, and the document set is matched to the destination.

Operational specifications

SpecDetailNotes
MOQ by formCapsules and tablets from 1,000 units; softgels 1,000–2,000 for pilot; gummies and stick packs higher first runsPilot quantities are quoted per formula
Lead timeSampling 7–10 days; pilot run 4–6 weeks after formula and artwork approvalDepends on packaging component availability
DocumentsCoA per batch; certificate of origin; health certificate; MSDS where relevantExport document set matched to destination market
PackingAluminium blister, HDPE with desiccant, foil stick packPackaging chosen against stability protocol
TestingAssay by HPLC; stability protocol agreed before batch releaseRaw material CoA alone is not sufficient

How a project runs

01
Market and status check
You tell us the destination market. We confirm whether NMN or NR is permitted there and record the date of the check, because status changes.
02
Formula and packaging
We agree the precursor, dose and dosage form, then specify packaging against moisture and heat exposure. Aluminium blister or HDPE with desiccant is decided here.
03
Sample and assay
Sampling takes 7–10 days. Potency is measured by HPLC and the stability protocol is agreed before you approve the specification.
04
Pilot run
A pilot run takes 4–6 weeks after formula and artwork approval. MOQ is from 500 units for most forms.
05
Batch release and export
Each batch ships with a CoA and the export documents for the destination: certificate of origin, health certificate, MSDS where relevant.

Quality and certificates

The factory holds GMP (Intertek), ISO 9001:2015 (CQC), ISO 22000:2018 (CQC), HACCP (CQC), an NSF audit, Halal certification from the Halal Foundation Center and FDA facility registration verified through the US agent Registrar Corp. Scope matters: Halal is line- and product-specific, so gelatin gummies differ from capsules. FDA registration is not FDA approval; dietary supplements have no pre-market approval in the US. We do not claim any certificate for this ingredient that the factory does not hold.

GMP (Intertek)ISO 22000:2018HACCPISO 9001:2015Halal (line-specific)FDA facility registration

NAD+ supplements: what is actually in the capsule

"NAD+ supplement" is a marketing category, not an ingredient. The molecule on the artwork is almost never NAD+ itself — it is one of three precursors: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), or occasionally a nicotinamide or niacin form. Each has a different regulatory status, a different stability profile and a different cost per gram, and the label rarely makes the distinction clear enough. This page is about the manufacturing side: what the raw material really is, how to specify it, and where these products fail on stability and compliance.

NAD+ versus its precursors: getting the identity right

NAD+ is a dinucleotide and a large, charged molecule. Given orally it is not efficiently absorbed intact and is largely hydrolysed in the gut, which is why the commercially meaningful ingredients are the precursors that enter the salvage pathway. A brand that puts "NAD+ 500 mg" on the front of a pack while the supplement facts panel lists nicotinamide riboside is describing an outcome, not an ingredient, and that gap is a compliance risk in both the US and the EU.

The three practical options are: nicotinamide riboside chloride (NR-Cl), the best-documented of the group and the one with a European novel-food authorisation; nicotinamide mononucleotide (NMN), which has the largest consumer demand but a contested regulatory position in several markets; and reduced or plain nicotinamide, which is cheap and legal but does not support the same consumer story.

Because the regulatory position differs by market and has changed more than once in the last few years, the ingredient decision has to be made per destination market before formulation starts, not after artwork is approved. This is the single most common cause of a relaunch we see.

Raw material quality: what separates a good lot from a cheap one

NR-Cl and NMN are fermentation-derived, sold as white to off-white powders, and priced high enough per kilogram that purity differences are commercially significant. The assay is normally HPLC, but the parameters that actually cause problems are the ones that do not appear on the sales sheet.

For NMN, the anomer ratio matters: the biologically relevant form is beta-NMN, and material with a high alpha content can still pass a total-NMN assay. For NR, the chloride salt form, water content and residual solvent profile all affect stability and flow. Neither ingredient is cheap enough to accept a certificate that only reports a single percentage.

  • Assay by HPLC with the specific isomer or salt form stated (beta-NMN, NR chloride)
  • Water content by Karl Fischer — NR is hygroscopic and degrades faster above 1% water
  • Residual solvents and fermentation by-products
  • Heavy metals (lead, arsenic, cadmium, mercury) and microbiological limits
  • Appearance, bulk density and particle size — these drive capsule fill and blend uniformity

Stability: why these ingredients are harder than they look

Both NR and NMN degrade by hydrolysis to nicotinamide, and the rate depends strongly on water activity and temperature. In a two-piece capsule at 25 °C / 60% RH the loss over 24 months is usually manageable; in a gummy, a stick pack or any format with free water, it is much faster. A gummy with a typical water activity of 0.55–0.65 is a genuinely difficult matrix for a 300 mg NR claim.

The practical controls are a low-moisture formula, a desiccant in the bottle, an opaque or amber container, and a conservative overage supported by real stability data. We do not accept a 24-month claim on NR or NMN without accelerated data at 40 °C / 75% RH plus at least three to six months of real-time data on the finished pack, because the degradation curve is not linear.

There is also an assay trap: some methods quantify total nicotinamide-related compounds, so a degraded sample can still report a high number. The method has to resolve NR or NMN from nicotinamide, and the specification should include a limit on the degradation product.

Dosage forms and realistic potencies

Capsules dominate the category because they are the cheapest way to deliver 150–500 mg of a hygroscopic powder with no water in the system. Typical retail potencies are 150 mg and 300 mg for NR, and 250 mg and 500 mg for NMN; above 500 mg per serving the capsule count becomes a consumer-acceptance problem.

Tablets are possible but compression heat and residual moisture both push hydrolysis, so we usually advise against them for these ingredients unless the formula is specifically designed for it.

Powders and stick packs work well when the product is a flavoured drink mix with a low water activity and a foil laminate sachet. Gummies are the hardest format and the one where we see the largest gap between the label claim and the measured content after three months — if a gummy is required, the overage and the packaging have to be engineered together.

Compliance and documentation before launch

For NR chloride, the EU novel-food authorisation provides a framework and a specified use level, which makes the European launch path comparatively predictable. For NMN, the position in the EU is that it is not an authorised novel food, and in the US the FDA has stated that NMN is excluded from the dietary supplement definition following its investigation as a drug candidate — a position that has been contested in court but has not been resolved in a way that makes a US NMN supplement low-risk.

Whatever the ingredient, the technical file should contain the supplier's specification, a certificate of analysis for each lot, the stability data behind the shelf-life claim, the allergen and non-GMO statements, and the finished-product assay. Where a structure/function claim is used in the US, the disclaimer wording and the substantiation file should be signed off before the first print run.

We keep lot-specific documentation for every batch we manufacture so that a retailer's technical query, or a market surveillance request two years later, can be answered with the actual documents rather than a generic datasheet.

Questions brand owners ask

Can you supply NMN for the US market?+
NMN has been excluded from the dietary supplement definition in the US by FDA. That status must be re-verified for the destination market and the year before a formula is locked. We will confirm the current position with you before quoting, and we do not treat any regulatory status as permanent.
Is NR a drop-in replacement for NMN?+
Not legally. NR has been through the EU novel food process, while NMN has not been authorised as a novel food in the EU. The two precursors are not interchangeable across markets. The formula, label and claims may all change when you switch precursor or destination.
What dosage forms can you make?+
Hard capsules, often DRcaps-style acid-resistant, powder sachets and stick packs, and tablets. These are the typical forms for moisture- and heat-sensitive precursors. Packaging such as aluminium blister, HDPE with desiccant or foil stick pack is specified against the stability protocol.
How do you test potency?+
Assay is by HPLC. We provide a CoA per batch, and buyers should ask for the actual potency method and a stability protocol, not just a CoA on the raw material. We will discuss the method behind the number before you approve the specification.
What is the MOQ and lead time?+
MOQ is from 500 units for most capsule and tablet forms. Softgels can start at 1,000 pieces for a pilot; gummies and stick packs need higher first runs. Sampling takes 7–10 days and a pilot run takes 4–6 weeks after formula and artwork approval.
Do you provide export documents?+
Yes. Each batch ships with a CoA. Export documents include certificate of origin, health certificate and MSDS where relevant. The document set is matched to the destination market, and we serve the US, UK, EU, Canada, Australia, Middle East and Southeast Asia.

Start with the destination market

Tell us the market and the dosage form. We will confirm the current regulatory position for NMN or NR, then quote a pilot run from 500 units with a CoA and export documents.

Related pages